Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Negative myoclonus associated with tramadol use

  • Bae, Seong Yoon (Department of Neurology, Daegu Fatima Hospital) ;
  • Lee, Se-Jin (Department of Neurology, Yeungnam University College of Medicine)
  • Received : 2020.03.02
  • Accepted : 2020.04.01
  • Published : 2020.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Negative myoclonus (NM) is a shock-like jerky involuntary movement caused by a sudden, brief interruption of tonic muscle contraction. NM is observed in patients diagnosed with epilepsy, metabolic encephalopathy, and drug toxicity and in patients with brain lesions. A 55-year-old man presented with NM in both his arms and neck. He has taken medications containing tramadol at a dose of 80-140 mg/day for 5 days due to common cold. He had no history of seizures. Acute lesions were not observed during magnetic resonance imaging, and abnormal findings in his laboratory tests were not noted. His NM resolved completely after the discontinuation of tramadol and the oral administration of clonazepam. Our case report suggests that tramadol can cause NM in patients without seizure history or metabolic disorders, even within its therapeutic dose.

Keywords

References

  1. Rubboli G, Tassinari CA. Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management. Neurophysiol Clin 2006;36:337-43. https://doi.org/10.1016/j.neucli.2006.12.001
  2. Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord 2011;4:47-62. https://doi.org/10.1177/1756285610395653
  3. Eberhardt O, Topka H. Myoclonic disorders. Brain Sci 2017;7:103. https://doi.org/10.3390/brainsci7080103
  4. Kim JB, Jung JM, Park MH, Lee EJ, Kwon DY. Negative myoclonus induced by gabapentin and pregabalin: a case series and systematic literature review. J Neurol Sci 2017;382:36-9. https://doi.org/10.1016/j.jns.2017.09.019
  5. Brefel-Courbon C, Gardette V, Ory F, Montastruc JL. Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin 2006;36:333-6. https://doi.org/10.1016/j.neucli.2006.12.003
  6. Jovanovic-Cupic V, Martinovic Z, Nesic N. Seizures associated with intoxication and abuse of tramadol. Clin Toxicol (Phila) 2006;44:143-6. https://doi.org/10.1080/1556365050014418
  7. Talaie H, Panahandeh R, Fayaznouri M, Asadi Z, Abdollahi M. Dose-independent occurrence of seizure with tramadol. J Med Toxicol 2009;5:63-7. https://doi.org/10.1007/BF03161089
  8. Boostani R, Derakhshan S. Tramadol induced seizure: a 3-year study. Caspian J Intern Med 2012;3:484-7.
  9. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879-923. https://doi.org/10.2165/00003088-200443130-00004
  10. Rehni AK, Singh I, Kumar M. Tramadol-induced seizurogenic effect: a possible role of opioid-dependent gamma-aminobutyric acid inhibitory pathway. Basic Clin Pharmacol Toxicol 2008;103:262-6. https://doi.org/10.1111/j.1742-7843.2008.00276.x
  11. Pappert EJ, Goetz CG, Stebbins GT, Belden M, Carvey PM. 5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. Eur J Pharmacol 1998;347:51-6. https://doi.org/10.1016/S0014-2999(98)00086-7
  12. Pranzatelli MR. Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists. Arch Neurol 1994;51:605-17. https://doi.org/10.1001/archneur.1994.00540180083018
  13. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000;41:479-81. https://doi.org/10.1111/j.1528-1157.2000.tb00192.x
  14. Park KD, Kim MK, Lee SJ. Negative myoclonus associated with pregabalin. Yeungnam Univ J Med 2018;35:240-3. https://doi.org/10.12701/yujm.2018.35.2.240
  15. Li JY, Cunic DI, Paradiso G, Gunraj C, Pal PK, Lang AE, et al. Electrophysiological features of myoclonus-dystonia. Mov Disord 2008;23:2055-61. https://doi.org/10.1002/mds.22273